No material company-specific news briefings were available in the verified context for the period ending 2026-09-11. The most recent regulatory filings and institutional ownership disclosures as of the generation date informed this report [Brief - 2026-08-15]. Medtronic plc continued to operate across its diversified medical device portfolio during this period, with the data below drawn from its most recent quarterly filings and ownership disclosures.
For the trailing twelve months ending 2026-07-31, Medtronic recorded revenue of $37.54 billion, representing year-over-year growth of 13.73%. Net income for the same period stood at approximately $430 million, yielding a net margin of 1.15%. Gross margin was reported at 51.95% and operating margin at 18.08%. Earnings per share grew 40.74% year-over-year. The company held $1.69 billion in cash against total debt of $24.68 billion. The market capitalisation stood at approximately $117.93 billion, with a price-to-earnings ratio of 22.69 [SEC 10-Q - MDT - 2026-07-31].
Insider activity in September 2026 recorded three transactions with a net direction of selling, amounting to a net disposal value of approximately $138,883 [SEC Form 4 - MDT - 2026-09]. On the institutional side, four notable firms opened new positions in MDT during the most recent 13F reporting period: Citadel (Ken Griffin), AQR Capital (Cliff Asness), Millennium (Izzy Englander), and Bridgewater (Ray Dalio). These simultaneous initiations across multiple large institutions represent the primary trigger for this report [SEC 13F - Citadel - Q2 2026] [SEC 13F - AQR Capital - Q2 2026] [SEC 13F - Millennium - Q2 2026] [SEC 13F - Bridgewater - Q2 2026].
The prevailing macroeconomic backdrop as of the generation date shows the 10-year US Treasury yield at 4.94% and the 2-year yield at 4.67%, producing a normal yield curve shape [FRED DGS10] [FRED DGS2]. This interest rate environment is relevant context for a company carrying $24.68 billion in total debt, as borrowing costs and refinancing conditions remain a structural consideration within Medtronic's capital structure.